{
    "clinical_study": {
        "@rank": "70674", 
        "arm_group": [
            {
                "arm_group_label": "Blood eosinophil count \u2264 400/\u00b5l"
            }, 
            {
                "arm_group_label": "Blood eosinophil count > 400/\u00b5l"
            }
        ], 
        "brief_summary": {
            "textblock": "To explore the relationship between blood eosinophil counts, asthma exacerbations and\n      patient asthma control using a large primary care based research database"
        }, 
        "brief_title": "The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled\n      corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to\n      fewer exacerbations than management adhering to Global Initiative for Asthma (GINA)\n      guidelines. However the use of sputum to measure eosinophil levels is expensive and\n      impractical within a clinical setting. This study explores the use of blood-eosinophil\n      levels as a clinical predictor for exacerbations and asthma control within a UK primary care\n      dataset."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient aged 12-80 at date of last eosinophil count\n\n          -  Asthma diagnosis at any time\n\n          -  Blood Eosinophil reading in patient record (numeric count expressed in \u00b5l) at least\n             one year prior to last data extraction\n\n          -  Two years of continuous data\n\n        Exclusion Criteria:\n\n          -  Any other chronic respiratory diseases\n\n          -  Eosinophil counts >5000/\u00b5l (outliers)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "12 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "A retrospective database analysis of asthma patients with a valid eosinophil count (where\n        valid: numeric value expressed as /\u00b5l at least one year prior to last data extraction)\n        with at least one year of data of prior to the date of eosinophil count (baseline period)\n        and one year of data post recorded eosinophil count (outcome period)."
            }
        }, 
        "enrollment": {
            "#text": "130248", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140541", 
            "org_study_id": "R05812"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Asthma", 
            "Blood eosinophils", 
            "Sputum eosinophils", 
            "Clinical predictor", 
            "UK primary care", 
            "Global Initiative for Asthma (GINA)"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": [
            {
                "url": "http://www.optimumpatientcare.org/Html_Docs/OPCRD.html"
            }, 
            {
                "url": "http://www.cprd.com/intro.asp"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Cambridge", 
                    "country": "United Kingdom", 
                    "zip": "CB24 3BA"
                }, 
                "name": "Research in Real Life Ltd"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils", 
        "overall_official": {
            "affiliation": "University of Aberdeen", 
            "last_name": "David Price, Prof, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Defined as:\nAmerican Thoracic Society / European Respiratory Society (ATS/ERS) task force definition: Asthma related hospital admissions OR accident and emergency  (A&E) room attendance OR Use of acute oral steroids\nClinical definition: ATS/ERS definition including any GP consultations for lower respiratory related tract infections (LRTIs) treated with antibiotics", 
                "measure": "Exacerbations", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Defined as:\nRisk domain asthma control: No Asthma-related  hospital attendance, A&E attendance, out-patient department attendance, no prescriptions for acute oral steroids and no GP consultations for LRTIs treated with antibiotics\nOverall asthma control: Risk domain asthma control definition, including average daily dose of \u2264200mcg salbutamol", 
                "measure": "Asthma control", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140541"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Research in Real-Life Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Teva Pharmaceuticals USA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Research in Real-Life Ltd", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}